StockData

Nektar Therapeutics vs Tango Therapeutics

NKTR and TNGX side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How NKTR and TNGX compare

Tango Therapeutics is the larger company, worth 3.3 times as much as Nektar Therapeutics ($4.1B against $1.2B).

Tango Therapeutics grew revenue faster over the last twelve months (121% versus −43.9% for Nektar Therapeutics).

Tango Therapeutics keeps more of each dollar of sales as profit, with a net margin of −230% compared with −297% at Nektar Therapeutics.

Tango Therapeutics scores higher on the StockData Score (10 against 9 for Nektar Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricNKTRTNGX
Size and price
Market cap$1.2B$4.1B
Share price$36.44$24.17
Change, 1 year−32.5%213%
Change, 5 years−78.3%134%
Beta (5Y)0.631.55
Employees63137
StockData Score
Total score910 (better)
Valuation score1 (better)0
Growth score12 (better)
Performance score22
Health score56 (better)
Dividend score00
Valuation
P/S22.5× (better)75.7×
P/B1.4× (better)4.0×
FCF yield−16.8%−3.5% (better)
Fair value–$9.65
Margin of safety–−150%
Growth
Revenue growth (TTM)−43.9%121% (better)
Revenue growth, 5Y average−18.4%52.1% (better)
Profitability
Gross margin100%–
Operating margin−254%−253% (better)
Net margin−297%−230% (better)
FCF margin−378%−268% (better)
Return on equity−37.3%−21.3% (better)
Return on invested capital−1186%–
Financial health
Debt / equity0.000.00
Current ratio10.4250.82 (better)
Altman Z-score−0.6749.39 (better)
Piotroski F-score34 (better)
Dividends and buybacks
Buyback yield0.00%–
Shareholder yield0.00%0.00%
Ownership
Held by institutions105%127%
Held by insiders0.46%11.7%
Insider net buying, 12 months−$2.2M (better)−$8.1M
Short interest, % of float19.9%32.4%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.